Organic nitrates have been a mainstay of treatment for angina pectoris for more than a century. Their principal mode of action is through the reduction of myocardial oxygen consumption via venodilatation with a consequent reduction in preload and an increase in myocardial oxygen supply via dilatation of the large coronary arteries.
In 1967 it was shown that pharmacological doses of glyceryl trinitrate could produce inhibition of platelet aggregation in vitro,' and over the last decade it has become clear that intravenous infusions of organic nitrates cause inhibition of platelet aggregation at therapeutic doses. [2] [3] [4] [5] [6] It is thought that the in vivo antiplatelet effects of organic nitrates are mediated by their metabolism to nitric oxide, which stimulates soluble guanylate cyclase in platelets with synthesis of cyclic guanosine monophosphate.7 It has been suggested that this effect on platelets may be responsible for at least part of the clinical benefit seen with organic nitrates in acute myocardial infarction and unstable angina.68
Despite the effects of glyceryl trinitrate on platelets after intravenous infusion, attempts to show an antiplatelet effect after the administration of topical or oral organic nitrates have been unsuccessful.9 10 In this study we identified the optimum conditions for detecting inhibition of platelet aggregation by nitric oxide in whole blood and then used this method to show an effect of transdermal glyceryl trinitrate on platelet aggregation in normal volunteers.
Methods

EXPERIMENTAL
The initial phase of this study was to identify the optimum conditions to detect the inhibition of platelet aggregation by nitric oxide in whole blood. Samples of citrated whole blood from normal volunteers, or platelet rich plasma derived from it," were stirred at 37°C in the presence of nitric oxide and also in the presence of various agents that could be expected to amplify the effect of nitric oxide on platelet aggregation. These always produced smooth dose-response curves and this was the agent chosen for further investigation.
Further experiments were performed using citrated whole blood (instead of platelet rich plasma) containing 100 pmol/l MB 22948 (0-5 ml). Here, a much greater volume of the saturated solution of nitric oxide (100 pul) produced only slight inhibition of aggregation; iloprost (0-5 ng/ml) still partially inhibited aggregation; nitric oxide in combination with iloprost produced a further inhibition of platelet aggregation.
In the second part of this study we chose and applied what we considered to be the optimum conditions to try to detect an effect of glyceryl trinitrate on platelet aggregation in whole blood after transdermal administration. The method chosen was as follows. Blood was withdrawn and collected into tubes that contained an anticoagulant (trisodium citrate) and MB 22948. The final concentrations of citrate and MB 22948 in the blood were 10-6 mmolIl and 100 pumol/l respectively.
Immediately after collection, aliquots of the blood were transferred to tubes that contained either 1, 3, or 10 pmol/l adenosine diphosphate together with 0, 0-5, or 1 ng/ml iloprost. (The concentrations given are final concentrations in the blood.) Samples were stirred for exactly 60 Platelet aggregation was measured before and one and two hours after patch application.
Heart rate and blood pressure were also measured after 10 minutes of supine rest before each venepuncture. A parallel series of investigations was performed with the same volunteers on a different day without application of a glyceryl trinitrate patch. The local ethics committee approved the study and all the volunteers provided informed consent. Aspirin and other antiplatelet drugs were forbidden during 10 days before blood sampling.
Results
INHIBITION OF PLATELET AGGREGATION AFTER TRANSDERMAL ADMINISTRATION OF GLYCERYL TRIN ATE
The method chosen to try to detect an effect of transdermal glyceryl trinitrate on platelets was to measure platelet aggregation in whole blood in response to adenosine diphosphate in the presence of MB 22948. The effect of two concentrations of iloprost on the extent of aggregation were also investigated. The table gives the results obtained before and after application of the glyceryl trinitrate patch.
The results show that application of a glyceryl trinitrate patch leads to a small but significant reduction in platelet aggregation at one and two hours, in the absence and presence of iloprost. There is a trend towards more inhibition at two hours than at one hour (figs 1-3). There was no significant change in heart rate or blood pressure on either study day (results not shown). ,, 1 I, 1 11 ,,,
Adenosine diphosphate (gmol/1) Figure 1 Platelet aggregation in whole blood in response w adenosine diphosphate before (0 hours) and one and two hours after the application of a glyceryl trinitrate patch. The blood contained MB 22948 only. **P < 0-02; *P < 0-03. Adenosine diphosphate (p Figure 3 Platelet aggregation in whole blood to adenosine diphosphate before (0 hours) amu hours after the application of a glyceryl trinitr The blood contained MB 22948 and iloprost **P < 0-02; *P < 003.
No significant inhibition of plat gation was observed on the control of the concentrations of adenosii phate used, either in the absence c of iloprost. 
Discussion
